RESUMEN
Research on microplastics (MPs) is gaining more attention in the soil environment, but their impact on soil microbiota and related nitrogen processes remains poorly understood. Nitrous oxide (N2O) is one of the important greenhouse gases of the nitrogen cycle in agricultural soil, which mainly originates from microbial-mediated nitrogen (N) transformation processes. Microplastics can influence soil nitrogen transformation, as well as nitrogen-related functional enzymes and genes, and its enrichment may profoundly affect the N2O emissions in soil. However, because of the complexity of the properties of MPs, variations in experimental conditions, and spatial-temporal scales, the results on the effects of MPs on soil N2O emissions, nitrogen content, enzymes activities, and nitrogen functional genes remain inconsistent. Additionally, there is a lack of research conducted at broader experimental scales (e.g., pot scale), from diverse perspectives (e.g., denitrification or DNRA), and using advanced techniques (e.g., stable isotope approaches) to elucidate the underlying mechanisms. Therefore, to comprehend the environmental risk of MPs on soil from multiple perspectives, this review summarized the impact of MPs on soil N cycling from previous published research to provide a knowledge basis and gain holistic insights into the potential impact of soil microplastic enrichment on N2O emission patterns in agricultural soils under climate change conditions.
RESUMEN
BACKGROUND: Current guidelines recommend oral anticoagulation (OAC) following transcatheter aortic valve replacement (TAVR) in patients with clinical indication, but the optimal antithrombotic regimen remains uncertain. We aimed to compare the efficacy and safety of non-vitamin K oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in patients undergoing TAVR with concomitant indication of OAC. HYPOTHESIS: Comparing with VKAs therapy, NOACs are similar in reducing the all-cause mortality and major bleeding in post-TAVR patients requiring OAC medication. METHODS: We searched the databases of PubMed, Embase, and Cochrane library databases to identify studies that investigated NOACs versus VKAs after TAVR in patients with another indication of OAC, which were published before 28th September 28, 2021. The effectiveness of outcomes was all-cause mortality and stroke or systemic embolism, while the main safety outcome was major and/or life-threatening bleeding. The hazard ratio (HR) with 95% confidence interval (CI) was used as a measure of treatment effect. RESULTS: Our search identified eight studies. We included 4947 post-TAVR patients with another indication of OAC allocated to the NOAC (n = 2146) or VKA groups (n = 2801). There were no significant differences in the all-cause mortality (HR: 0.91, 95% CI: 0.77-1.08, p = .29, I2 = 47%), stroke or systemic embolism (HR: 0.96, 95% CI: 0.68-1.37, p = .84, I2 = 0%), and major and/or life-threatening bleeding (HR: 1.09, 95% CI: 0.89-1.32, p = .40, I2 = 30%) in both groups. CONCLUSION: Among post-TAVR patients who required OAC therapy, NOACs therapy compared to VKAs is similar in reducing the all-cause mortality, stroke or systemic embolism, and major and/or life-threatening bleeding events.